Jin Rong Jie·2025-05-09 12:07Group 1 - The core viewpoint of the articles highlights the financial performance and market position of BeiGene, a global biotechnology company focused on innovative drug development and commercialization [1][2] - As of May 9, BeiGene's stock closed at 243.52 yuan, reflecting a 2.15% increase, with a market capitalization of 341.576 billion yuan and a price-to-book ratio of 14.13 [1] - The latest financial report for the year 2024 shows that BeiGene achieved a revenue of 27.214 billion yuan, representing a year-on-year growth of 56.19%, while the net profit was -4.978287 million yuan, a decrease of 25.87% [1] Group 2 - A total of 219 institutions hold shares in BeiGene, including 218 funds and 1 brokerage, with a combined holding of 37.9477 million shares valued at 9.063 billion yuan [1] - The company’s sales gross margin stands at 84.44%, indicating a strong profitability in its operations [1] - In comparison to industry averages, BeiGene's price-to-earnings ratio (TTM) is -107.93, while the industry average is 57.12, suggesting a significant divergence in valuation metrics [2]